We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Pilot Study to Evaluate the Safety and the Efficacy of the Matrix and Cells Obtained by the AmeaCell® Device and Intended for the Filling of Wrinkles on the Face. (SKINMAT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03529292
Recruitment Status : Completed
First Posted : May 18, 2018
Last Update Posted : December 6, 2021
Sponsor:
Information provided by (Responsible Party):
Symbioken

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The purpose of this study is to evaluate the filling using the Matrix and Cells, obtained by the Ameacell® device from autologous adipose tissue and intended for the filling of wrinkles on the face.

Condition or disease Intervention/treatment Phase
Skin Aging Device: AmeaCell Not Applicable

Detailed Description:

The purpose of this study is to evaluate the filling using the Matrix and Cells, obtained by the Ameacell® device from autologous adipose tissue and intended for the filling of wrinkles on the face.

This is a mono-center, pilot study in 24 subjects

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 23 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Pilot Study to Evaluate the Safety and the Efficacy of the Filling Using the Matrix and Cells, Obtained by the AmeaCell® Device From Autologous Adipose Tissue and Intended for the Filling of Wrinkles on the Face.
Actual Study Start Date : July 9, 2018
Actual Primary Completion Date : February 1, 2021
Actual Study Completion Date : February 1, 2021
Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Matrix and Cells obtained by the AmeaCell® device Device: AmeaCell
Lipoaspirate obtained from liposuction is treated by the AmeaCell® device in order to obtain Matrix and Cells which contains cellular phase and matrix phase. The Matrix ancd Cells are injected in the same patient as facial wrinkles filler.


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Incidence of the Adverse Event(s) [ Time Frame: From selection up to 12 months after the injection ]
    Adverse events will be investigated and recorded at each visit by the investigator

  2. Local tolerance [ Time Frame: First 4 weeks after the injection ]
    The subject will record daily the local tolerance in a diary card. Signs of erythema, edema, bruising, discolouration, pain / tenderness, and pruritus will be noted and scored from 0 (none) to 3 (severe).


Secondary Outcome Measures :
  1. Wrinkle Severity Rating Scale (WSRS) Evaluation for the nasolabial folds [ Time Frame: Change from baseline at month 1, 6 and 12 ]

    The Wrinkle Severity Rating Scale (WSRS) is a 5-point reference scale with photographs that classifies deep facial wrinkles (Nasolabial Folds). The grading is performed on both sides to give a reliable and reproducible gradation of the depth of the folds. The grading of the wrinkles is made by the investigator according to the following grades:

    Grade 1 No visible nasolabial folds; continuous skin line Grade 2 Shallow but visible nasolabial folds with a slight indentation Grade 3 Moderate deep nasolabial folds; visible at normal appearance Grade 4 Very long and deep nasolabial folds; prominent facial feature ;< 2mm visible fold if stretched Grade 5 Extreme deep long nasolabial folds; 2-4mm V shaped fold if stretched


  2. Depth of the wrinkles by 3D picture [ Time Frame: Change from baseline at month 1, 6 and 12 ]
  3. Global Aesthetic Improvement Scale (GAIS) Evaluation [ Time Frame: Change from baseline at month 1, 6 and 12 ]

    The GAIS scale ("Global Aesthetic Improvement Scale") is a judgment scale noting the apparent overall aesthetic improvement, in comparison with the aspect observed before the injection (on a photograph taken during the day of inclusion). Rating categories are: "Worse"; "No change"; "Slightly improved", "Much improved"; "Very much improved".

    Evaluations are carried out by the investigator but also by the subject himself according to the same criteria.



Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Man or woman from 18 to 70 years
  • Subject wishing liposuction
  • Subject wishing a filling of facial wrinkles for aesthetic purposes
  • Subject for which it is possible to achieve a puncture of adipose tissue of at least 150ml so that after decantation or centrifugation there remains 100ml of adipose tissue
  • Facial wrinkles that can be treated with the Matrix and Cells volume of approximately 12ml
  • Grade of wrinkles at level 2 minimum of the nasolabial fold according to the WSRS scale
  • Free, informed and written consent
  • Affiliate or beneficiary of a social security scheme

Exclusion Criteria:

  • Pregnant or breastfeeding woman or planning to be pregnant
  • Woman of childbearing age without effective contraceptive
  • Subject having a filling of facial wrinkles with hyaluronic acid or by a method of lipofilling (injection of adipose tissue) in the 12 months prior to the enrollment
  • Subject who has undergone treatment of facial wrinkles by injection of botulinum toxin, by mesotherapy or cosmetic procedure (laser, photo modulation, intense pulsed light, radio frequency, dermabrasion, chemical peel or other ablative procedures) within 12 months at least prior to enrolment or subject who is planning this type of procedure during the study
  • Subject who has received semi-permanent dermal fillers or permanent facial implants or who is planning to do this type of implant during the study
  • Subject having history of formation of hypertrophic scars or keloids
  • Subject having a skin disease or skin inflammation (e.g. acne, herpes, eczema, psoriasis, sclerosis) at the site to be treated or elsewhere on the body if suspected of spreading on the site to be treated
  • Subject with allergic contact dermatitis or a history of allergic contact dermatitis or a family history of allergic contact dermatitis
  • Presence of tattoo and / or scar in the treatment area that, in the opinion of the investigator, could interfere with the evaluation of the study
  • Diabetes (type I or type II)
  • Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV) or Hepatitis C Virus (HCV) seropositivity
  • Subject under anti-HIV treatment
  • Autoimmune disease
  • Immunodepression
  • History of phlebitis or pulmonary embolism
  • Major pathology involving the renal, hepatic, cardiovascular, immune and / or nervous system
  • Cancerous lesion on the face
  • Any other diseases that could, in the opinion of the investigator, be clinically significant and make the subject inappropriate for the study, alter the results of the study or increase the risk for the subject
  • Known hypersensitivity to cobalt
  • Known hypersensitivity to collagenase
  • Known or suspected allergy to lidocaine or any other amide anesthetic
  • History of known severe allergies (anaphylaxis, angioedema) for a product used in the study
  • Any contraindication to lipofilling surgery
  • Active smoking or subject who stopped smoking less than one month before the intervention
  • Radiotherapy treatment at the head and neck region.
  • Chemotherapy treatment
  • Treatment with anticoagulant or Nonsteroidal anti-inflammatory drug (NSAID) or any other substance known to increase clotting time during the 2 weeks prior to enrollment
  • Corticosteroids in the 6 weeks prior to enrollment
  • Subject having a metal-metal hip prosthesis
  • Subject under lidocaine or structurally related local anesthetic (e.g. bupivacaine) within 24 hours prior to enrollment
  • Subject having undergone general anesthesia for less than 8 days
  • Treatment with an oral or topical retinoid in the month prior to enrollment
  • Subject having a history of drug or alcohol addiction in the 12 months prior to enrollment
  • Participation in another research including an exclusion period still in progress at the time of enrollment
  • Person placed under guardianship or curatorship or under the protection of justice
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03529292


Locations
Layout table for location information
Belgium
Hôpital Erasme
Bruxelles, Belgium
Sponsors and Collaborators
Symbioken
Investigators
Layout table for investigator information
Principal Investigator: Dr Cuylits Hôpital Erasme, Bruxelles, BELGIUM
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Symbioken
ClinicalTrials.gov Identifier: NCT03529292    
Other Study ID Numbers: SYMB-SAF1701
First Posted: May 18, 2018    Key Record Dates
Last Update Posted: December 6, 2021
Last Verified: November 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No